Wire · opportunities
Definium's LSD-based anxiety, depression drug scores another trial win
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
Definium Therapeutics announced a second successful late-stage trial showing that its LSD-based drug DT120 significantly reduces symptoms of generalized anxiety disorder (GAD), improving its chances of FDA approval with a potential filing planned for early 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.
◆ ◆ The Wire takeaway
Your mental health biotech startup now faces a clearer regulatory path as psychedelic therapies move closer to FDA approval. Make early preparation to engage on clinical trial design and regulatory strategy in this emerging drug class.
◆ Coverage
3 sources · 14 Sep 2026
◆ Related on Wire
◆ Topics